AVONEX efficacy

AVONEX has been the subject of multiple studies. Efficacy and safety of AVONEX in patients with relapsing forms of multiple sclerosis (MS) were studied in the MSCRG clinical trial (Study 1) and the CHAMPS clinical trial (Study 2).1-3

The clinical effects of AVONEX were further analyzed in the long-term follow-up studies, CHAMPIONS (10 years) and ASSURANCE (15 years).4,5

Abbreviations: MSCRG, Multiple Sclerosis Collaborative Research Group; CHAMPS, Controlled High-Risk AVONEX Multiple Sclerosis Prevention Study; CHAMPIONS, Controlled High-Risk AVONEX Multiple Sclerosis Prevention Study in Ongoing Neurological Surveillance; ASSURANCE, ASSessment of Drug Utilization, EaRly TreAtmeNt, and Clinical OutcomEs.1-5

AVONEX pivotal trials

Study design and efficacy results from 2 multiyear clinical studies

See the data
Long-term follow-up studies

Results from AVONEX 10-year and
15-year extension studies

Examine the findings

Resources for you

Getting started

Get your patients started on therapy with the AVONEX Start Form

Download Start Form
One injection, once a week1

Explore once-a-week dosing and different dosage forms for your relapsing MS patients

Review AVONEX dosing
Streamline the process and support patient adherence

myBiogen is an online resource for starting and keeping patients on therapy

Sign up at myBiogen.com